fracture. Bone appears quite abnormal and muscle mass is greatly diminished.
and much-fractured leg bones almost always had thin cortices. waves in the left temporal region; technecium brain scan, increased uptake in the left frontotemporal region at the site of the bone erosion (see figure) ; and left carotid arteriogram normal. Skull biopsy (Professor Sissons, Institute of Orthopaedics): bony trabeculae showed intense focal osteoclastic resorption together with an irregular pattern of cement lines; the spaces between the trabeculae were occupied by vascular fibrous tissue. The appearances suggested Paget's disease. The patient was treated with phenobarbitone, 60 mg daily, and has had no further attacks.
Case 2-A West Indian of 38 was admitted to hospital in October 1976 having developed generalised involuntary convulsive movements with frothing at the mouth while sitting at home. He was confused and complained of headache on regaining consciousness five minutes later. A similar attack had occurred three years before, but there was no family history of epilepsy. Results of examination and investigations were as follows: no abnormal neurological signs; skull radiography, thickening of both vault tables with some invagination of the skull base at the foramen magnum; electroencephalography, a mild diffuse abnormality with left-sided emphasis but without paroxysmal changes; technecium brain scan, a large head with a broad band of activity around the periphery in all three views; cerebrospinal fluid normal; serum alkaline phosphatase 105 U/I (normal <90 U/l); urine hydroxyproline 0-72 mmol)24 h (94 6 mg!24 h) (normal 0-076-0 38 (10-50)); and serum calcium and phosphorus concentrations normal. The patient has had no further attacks since taking phenobarbitone 60 mg daily.
Comment
These cases illustrate the association of grand mal epilepsy with two types of Paget's disease of the skull-osteoporosis circumscripta and generalised thickening of the bone. It might be argued that the association is coincidental, as both are common diseases. In case 1, however, the focal features of the attack, together with focal abnormalities on the EEG at the site of the bony defect and the increased uptake on the gamma scan there, suggest the association is more than fortuitous. In case 2 the bony abnormality was generalised, but the relatively young age of the patient and late onset of the epilepsy suggest that the conditions are related.
In case 1 there was doubt about the diagnosis until confirmed by bone biopsy but case 2 showed typical x-ray appearances together with increased hydroproline excretion and serum alkaline phosphatase.
The explanation for the association can only be speculative, but the increased vascularity of the bone overlying the brain may have triggered the attacks. The finding of an abnormal isotope scan in epilepsy could be misleading if Paget's disease is not considered in the differential diagnosis. In case 1 a meningioma with bonie erosion was suggested, but bone biopsy gave the diagnosis. In case 2 the scan appearance was similar to chronic subdural haematoma.3
Culebras, A, Feldman, R G, and Fuger, C A, J3ournal of Neurological Science, 1974, 23, 307 . Gold is said' to be the most toxic drug in the Pharmacopoeia; none the less the use of gold treatment in progressive rheumatoid arthritis is steadily increasing. In a survey2 of deaths of patients taking medicaments, Girdwood found that gold was associated with the highest mortality rate of all drugs when the annual numbers of deaths reported to the Committee on Safety of Medicines (CSM) were related to the number of EC10 prescriptions for those drugs in England and Wales. Despite Girdwood's warnings that his data lacked scientific accuracy, his findings are often quoted without this warning.
Two possible sources of error may have combined to put gold at the top of the list. Firstly, the three drugs with the highest ratio of deaths to ECIO prescriptions were all hospital-based drugs-gold, phenindione, and warfarin-and therefore poorly represented by EC10 prescribing. Secondly, patients with rheumatoid arthritis receive many different drugs, all with different side effects, in varying amounts over the years. To test the hypothesis that Girdwood's figures were an overestimate, I obtained details of the CSM's reports of deaths from 1964 to 1976 in which the use of gold was mentioned, and the likely contribution of gold to the causation of each death was independently assessed. Finally, the amount of gold supplied in the UK in those years was ascertained.
Findings
From 1964 to 1976, reports of 46 deaths to the CSM listed gold treatment. Blood dyscrasia caused death in 39 cases (aplastic anaemia 30, agranulocytosis 5, thrombocytopenia 3, myeloproliferative disorder 1); gold was thought to be the probable cause in 16 cases, a possible cause in 17, and an unlikely cause in six. Some of these 39 patients had been taking other antirheumatic drugs known to cause blood dyscrasia: phenylbutazone 20, oxyphenbutazone 3, penicillamine 3, chlorambucil 2, and indomethacin 13. In the seven other cases the contribution of gold to the cause of death was even more unlikely; in six the gold had been discontinued years before death, and often other medications were more likely causes. The immediate causes of death were: renal disease attributed to indomethacin; gastric ulceration during prednisone and azathioprine treatment; hepatic necrosis and renal failure; Goodpasture-like syndrome with coagulation disorder
